MedTrace Logo

Heart Imaging in Children With Muscular Dystrophy

NCT01633242 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2019-09-13

No results posted yet for this study

Summary

Background:

\- Muscular dystrophy can affect the muscles used for heart function and breathing. Treatment usually involves drugs that help improve heart function. However, better types of heart imaging studies are needed to improve treatment of heart problems related to muscular dystrophy. Better heart imaging methods are especially needed for children with muscular dystrophy. Researchers want to test different heart imaging methods in children with muscular dystrophy. They will look at cardiac magnetic resonance imaging (MRI) and standard heart function tests.

Objectives:

\- To develop and test new methods for imaging the heart in children with muscular dystrophy.

Eligibility:

\- Children and adolescents between 8 and 17 years of age who have muscular dystrophy.

Design:

* Participants will be screened with a physical exam and medical history.
* Participants will provide a blood sample at the start of the study. They will also have heart function tests before having the imaging study.
* Participants will have a cardiac MRI scan that will last up to 60 minutes. Some tests will require a MRI contrast agent (a drug that helps the image appear more clearly on the scan).

Conditions

  • Muscular Dystrophy

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Andrew E Arai, M.D. · National Heart, Lung, and Blood Institute (NHLBI)

Eligibility

Min Age
8 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-24
Completion
2016-10-11

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01633242 on ClinicalTrials.gov